Low antibiotic doses combat Golden Staph

February 20, 2015 by Narelle Towie, Science Network WA
Dr Boulos and his team tested the drug on worms and cured them of infection. Credit: National Eye Institute

Local chemists have helped develop a class of antibiotics that kills drug-resistant superbugs in low doses.

Australian and US researchers used 3D computer modelling to design the new antibiotic, called Compound 10, and found that it can kill drug-resistant Staphylococcus aureus in worms at doses 10 times lower than other commonly used .

Methicillin-resistant Staphylococcus aureus (MRSA), also known as Golden Staph, is a growing problem in WA hospitals, leaving first-line antibiotics powerless to stop infection and significantly increasing rates of illness and death.

The new drug targets a bacteria-specific protein, called the mechanosensitive ion channel of large conductance (MscL), which stops the bacteria's from rupturing by acting as a valve and releasing solutes.

Flinders University research associate Dr Ramiz Boulos says MscL was an ideal target for drug research because it sits on the outer membrane of nearly all bacteria, but is not found in the human genome.

"What we have designed here is antibiotics that allow the bacteria to vomit to a point where they become really weak and they either die or they can be overcome by the host," Dr Boulos says.

Low antibiotic doses combat Golden Staph
A ball and stick representation of the antibiotic. Credit: Ramiz Boulos

"What the antibiotics do is they open this channel (MscL) more frequently and for longer periods of time."

UWA biochemist Edwin Tjandra, who spent months testing the toxicity of the drug on cultured , says the discovery is a major breakthrough in the battle against superbugs.

"I was looking at what concentration the drug kills immortalised skin cells and found there was no toxicity to eukaryotic cells until we used doses 10 times the minimum inhibitory concentration," Mr Tjandra says.

"I think it's very important for the treatment of MRSA."

Dr Boulos and his team tested the on worms and cured them of infection.

They hope that within five years, Compound 10 will move into human clinical trials, following more animal studies.

Dr Boulos says some of the compounds he was working with are new to chemistry and his team were extremely excited to find Compound 10 not only has antibacterial properties but is also so highly effective at killing Staphylococcus.

In low doses, Compound 10 did not harm the worm's cells (or had low cytotoxicity) but was highly potent to the bacteria.

"In the worm infection model we started to see therapeutic effects from 0.2 micrograms per milliltre."

"The cytotoxicity concentration occurs at 50 micrograms per milliltre, so that's a 250 fold difference, and that's much better than commercial antibiotics.

Explore further: New antibiotic holds promise against antibiotic-resistant infections

Related Stories

New antibiotic holds promise against antibiotic-resistant infections

February 16, 2015
Estimates of deaths from methicillin-resistant Staphylococcus aureus (MRSA) in the United States range upwards of 19,000 annually. Around 1960, when Staphylococcus aureus developed resistance to first-generation penicillin, ...

Getting ahead of antibiotic-resistant bacteria

February 6, 2015
The prevalence of antibiotic-resistant bacteria has turned new drug development into a high-stakes chess game, with researchers always trying to anticipate a disease bacteria's next move or mutation to make sure new antibiotics ...

Scientists develop compound to fight MRSA

January 29, 2015
Microbiologists and chemists at the University of South Florida have developed and patented a synthetic compound that has shown antibiotic action against methicillin resistant Staphylococcus aureus, also known as MRSA, which ...

Recommended for you

A new approach to developing a vaccine against vivax malaria

September 21, 2018
A novel study reports an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study led by Hernando A. del Portillo and Carmen Fernandez-Becerra, ...

Pre-clinical success for a universal flu vaccine offers hope for third generation approach

September 21, 2018
Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Communications.

Researchers define possible molecular pathway for neurodegeneration in prion diseases

September 21, 2018
A new study has shed light on the mechanisms underlying the progression of prion diseases and identified a potential target for treatment.

Fighting a deadly parasite: Scientists devise a method to store Cryptosporidium, aiding vaccine research efforts

September 21, 2018
In May, just before one of the hottest summers on record, the U.S. Centers for Disease Control and Prevention issued a warning about diseases lurking in recreational water facilities like swimming pools and water playgrounds. ...

Scientists make significant discovery in the fight against drug-resistant tuberculosis

September 20, 2018
A team of scientists have identified a naturally occurring antibiotic that may help in the fight against drug-resistant Tuberculosis.

Anti-cancer drugs may hold key to overcoming antimalarial drug resistance

September 20, 2018
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.